Veeva and OpenEvidence Join Forces to Launch Open Vista for Enhanced Clinical Trials

Veeva and OpenEvidence Unite to Transform Clinical Trials with Open Vista

In a groundbreaking collaboration announced on October 16, 2025, Veeva Systems (NYSE: VEEV) and OpenEvidence revealed their long-term partnership to develop and market a new platform called Open Vista. This innovative platform is set to harness the power of artificial intelligence (AI) to revolutionize the way patients access clinical trials and receive cutting-edge therapies.

Veeva Systems has established itself as a leader in cloud solutions tailored for life sciences, providing vital software, data, and consulting services to over 1,500 clients, from major biopharmaceutical companies to emerging biotech firms. On the other hand, OpenEvidence has become the fastest-growing decision support platform for clinical practitioners in the United States, with more than 40% of U.S. physicians engaging with its AI-enabled clinical decision support right at the point of care.

The Need for Improved Access to Clinical Trials

As per Daniel Nadler, CEO of OpenEvidence, clinical trials represent a beacon of hope for many patients suffering from severe illnesses who have exhausted traditional first and second-line therapies. The partnership aims to bridge the gap between peer-reviewed medical evidence and clinical practice, providing a streamlined approach for connecting physicians and patients with relevant clinical trials.